To understand, at the molecular and cellular level how oncogenes control neuroendocrine plasticity, how this contributes to metastasis and chemoresistance.
To characterize the mechanism of pancreatic neuroendocrine tumour progression using mouse models of pancreatic cancer.
Farrell, A. S., Joly, M. M., Allen-Petersen, B. L., Worth, P. J., Lanciault, C., Sauer, D., Link, J., Pelz, C., Heiser, L. M., Morton, J. P.,Muthalagu, N., Hoffman, M. T., Manning, S. L., Pratt, E. D., Kendsersky, N. D., Egbukichi, N., Amery, T. S., Thoma, M. C., Jenny, Z. P., Rhim, A. D., Murphy, D. J., Sansom, O. J., Crawford, H. C., Sheppard, B. C. & Sears, R. C. (2017). "MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance", Nat Commun, 8, pp. 1728.
Port, J., Muthalagu, N., Raja, M., Ceteci, F., Monteverde, T., Kruspig, B., Hedley, A., Kalna, G., Lilla, S., Neilson, L., Brucoli, M., Gyuraszova, K., Tait-Mulder, J., Mezna, M., Svambaryte, S., Bryson, A., Sumpton, D., McVie, A., Nixon, C., Drysdale, M., Esumi, H., Murray, G. I., Sansom, O. J., Zanivan, S. R. & Murphy, D. J (2018). "Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress", Cancer Discov, 8, pp. 632-647.
Repression of Type I Interferon pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B cells in Pancreatic Ductal Adenocarcinoma (2020). "Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu R, Whyte, D., Hedley, A., Laing, S., Upstill-Goddard, R., Shaw, R., Neidler, S., Gyuraszova, K., Nixon, C., Clark, W., Biankin, A., Carlin, L., Coffelt, S., Sansom, O. J., Morton, J. & Murphy, D. J.", Cancer Discov, 10, pp. 872-87.